Academic Journal
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long term disease control : an analysis from the Lymphoma Working Party Of the EBMT
| العنوان: | Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long term disease control : an analysis from the Lymphoma Working Party Of the EBMT |
|---|---|
| المؤلفون: | S. P. Robinson, A. Boumendil, H. Finel, H. Schouten, G. Ehninger, J. Maertens, C. Crawley, N. Russell, W. Anders, D. Blaise, I. Yakoub Agha, A. Ganser, L. Castagna, L. Volin, J. Cahn, S. Montoto, P. Dreger, A. Rambaldi |
| المساهمون: | S.P. Robinson, A. Boumendil, H. Finel, H. Schouten, G. Ehninger, J. Maerten, C. Crawley, A. Rambaldi, N. Russell, W. Ander, D. Blaise, I. Yakoub Agha, A. Ganser, L. Castagna, L. Volin, J. Cahn, S. Montoto, P. Dreger |
| سنة النشر: | 2016 |
| المجموعة: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| مصطلحات موضوعية: | follicular lymphoma, reduced intensity allogeneic stem cell transplant, Settore MED/15 - Malattie del Sangue |
| الوصف: | Background: Patients with follicular lymphoma (FL) relapsing after an autologous transplant (autoSCT) may be treated with a variety of therapies, including a reduced intensity allogeneic transplant (RICalloSCT). We conducted a retrospective analysis of a large cohort of patients undergoing RICalloSCT for FL in this setting. A total of 183 patients, median age 45 years (range 21-69), had undergone an autoSCT at a median of 30 months before the RICalloSCT. Before the RICalloSCT, they had received a median of four lines (range 3-10) of therapy and 81% of patients had chemosensitive disease and 16% had chemoresistant disease. Grafts were donated from sibling (47%) or unrelated donors (53%). With a median follow-up of 59 months, the non-relapse mortality (NRM) was 27% at 2 years. The median remission duration post-autoSCT and RICalloSCT was 14 and 43 months, respectively. The 5-year relapse/progression rate, progression-free survival and overall survival were 16%, 48% and 51%, respectively, and were associated with age and disease status at RICalloSCT. These data suggest that an RICalloSCT is an effective salvage strategy in patients with FL recurring after a prior autoSCT and might overcome the poor prognostic impact of early relapse after autoSCT. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/26961149; info:eu-repo/semantics/altIdentifier/wos/WOS:000377427900019; volume:27; issue:6; firstpage:1088; lastpage:1094; numberofpages:7; journal:ANNALS OF ONCOLOGY; http://hdl.handle.net/2434/431509; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84974799171 |
| DOI: | 10.1093/annonc/mdw124 |
| الاتاحة: | http://hdl.handle.net/2434/431509 https://doi.org/10.1093/annonc/mdw124 |
| Rights: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.E288090 |
| قاعدة البيانات: | BASE |
كن أول من يترك تعليقا!